Amlodipine/Telmisartan/Indapamide

氨氯地平/替米沙坦/吲达帕胺

Report date: 2026/04/22 20:01:10

Base Information

Drug NameAmlodipine/Telmisartan/Indapamide
Drug Alias Name吲达帕胺/氨氯地平/替米沙坦Amlodipine+Telmisartan+Indapamide替米沙坦/吲达帕胺/氨氯地平Indapamide/Amlodipine/TelmisartanTelmisartan/Indapamide/Amlodipine +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsSymporters inhibitorsVoltage-gated calcium channel blockers
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channelSymporters
Therapy Area/IndicationsHemorrhagic StrokeCognition DisordersHypertension +[6] 
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/06/05
Country/TerritoryCzechiaUnited StatesPoland +[9] 
CombinationsYes IndapamideAmlodipine BesylateTelmisartan
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesThe George Institute For Global Health
China Registration ClassN/A

Develop Information

Active CompaniesImperial College LondonAzurity Pharmaceuticals IncGeorge Medicines PTY Ltd
Inactive CompaniesThe George Institute For Global Health
Active IndicationsHypertension
Inactive IndicationsHemorrhagic StrokeCognition DisordersCerebral Hemorrhage +[5] 

Other Information

ATC CodeN/A
Related LinksN/A